73d5ada9bb343946c8db104b740157fe.jpeg

Combative U.S. FDA panel votes against Biogen Alzheimer's drug

Combative U.S. FDA panel votes against Biogen Alzheimer's drugThe FDA still could decide to approve the drug, aducanumab, making it the first new Alzheimer’s treatment in decades. Several of the 11 panel members expressed resentment that the FDA’s early view of aducanumab – which was made public on Wednesday – was biased toward a favorable outcome for Biogen.


Source link

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Leave a Reply